Royal National Hospital for Rheumatic Diseases

Recent papers from Royal National Hospital for Rheumatic Diseases

1. Interventions aimed at advancing gender equity in rheumatology: Insights from the Coalition for Health and Gender Equity (CHANGE) surveyAutoimmunity Reviews · 2026
2. Perspectives of sedentary behaviour, physical activity, and health messaging among people with fibromyalgia: a qualitative studyRheumatology Advances in Practice · 2026
3. Medication use during pregnancy and pregnancy outcomes in women with immune mediated inflammatory diseases: a UK-based matched cohort studyLara D. Veeken · 2026
4. Autoantibodies to 14-3-3η: A Novel Diagnostic Biomarker for Axial SpondyloarthritisThe Journal of Rheumatology · 2026
5. Autoantibodies to 14-3-3η Improves Discriminative Performance of CRP and HLA-B27 to Differentiate People with Radiographic axSpA from Those with Mechanical Back PainThe Journal of Rheumatology · 2026
6. Real-world treatment patterns in stage III and IV melanoma patients: insights from a global multi-center chart review studyFrontiers in Immunology · 2026
7. The SLICC/ACR Damage Index, assessed using a community-based electronic healthcare record, predicts mortality in systemic lupus erythematosus patients: results from the UK Clinical Practice Research DatalinkRheumatology Advances in Practice · 2026
8. Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 Annual MeetingThe Journal of Rheumatology · 2026
9. Bimekizumab Improves Health Status and Work Productivity, With Reduced Productivity Costs, to 3 Years in Axial Spondyloarthritis and Psoriatic ArthritisThe Journal of Rheumatology · 2026
10. Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic reviewRMD Open · 2026
11. Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysisAnnals of the Rheumatic Diseases · 2026
12. Efficacy of Ixekizumab in Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level: A Pooled Analysis of Phase III TrialsRheumatology and Therapy · 2026
13. The clinical utility of telangiectasia quantification as markers of vascular disease progression in systemic sclerosisLara D. Veeken · 2026
14. GRAPPA Debate: Is Plain Radiography in Psoriatic Disease Still Necessary?The Journal of Rheumatology · 2026
15. Holistic management of juvenile idiopathic arthritis across all ages: British Society for Rheumatology Guideline scopeRheumatology Advances in Practice · 2026
16. The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosusLara D. Veeken · 2026
17. Executive Summary: The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosusLara D. Veeken · 2026
18. Control of Inflammation and Sustained Improvements in Patient‐Reported Outcomes in Patients With Psoriatic Arthritis: Bimekizumab Two‐Year Results From Two Phase 3 StudiesACR Open Rheumatology · 2026
19. OA29 Developing the UK Rheumatology Occupational Therapy Capabilities Framework: A national co-produced initiativeLara D. Veeken · 2026
20. P172 Weight management and GLP-1 receptor agonists in psoriatic disease: insights from a survey of rheumatology and dermatology professionalsLara D. Veeken · 2026